The EMA’s Committee for Medicinal Products for Human Use recommended 17 drugs for approval at its December meeting, bringing the total for 2024 to 114. That is up from the 77 drugs recommended for approval in 2023, of which 39 were novel.
Tubulis GmbH has sealed a potential $415 million option and licensing deal under which it will apply proprietary technologies to discover an antibody-drug conjugate (ADC) against a solid tumor target for Gilead Sciences Inc.
The U.S. District Court for the Northern District of California ordered Lorik Papyan, who pleaded guilty three years ago to one count of unlicensed wholesale distribution of prescription drugs, to pay Gilead Sciences Inc. nearly $32 million in restitution to cover lost profits due to a counterfeit HIV drug scheme he was involved in.
Gilead Sciences Inc. has synthesized 4-aminopyrrolo[2,1-F][1,2,4]triazine C-nucleoside analogues acting as prodrugs of GS-441524 and reported to be useful for the treatment of viral infections.
Gilead Sciences Inc. terminated a potential $785 million licensing deal with Yuhan Corp. inked in 2019 to develop metabolic dysfunction-associated steatohepatitis (MASH) therapies.
Gilead Sciences Inc. terminated a potential $785 million licensing deal with Yuhan Corp. inked in 2019 to develop metabolic dysfunction-associated steatohepatitis (MASH) therapies.
Gilead Sciences Inc. and Genesis Therapeutics Inc. have entered into a strategic collaboration to discover and develop novel small-molecule therapies across multiple targets.
Friday the 13th could be a make-or-break day in the U.S. for Intercept Pharmaceuticals Inc.’s Ocaliva (obeticholic acid). That’s the day the company will make its case before the FDA’s Gastrointestinal Drugs Advisory Committee for turning an 8-year-old accelerated approval into traditional approval.
